ROCHESTER, NY / ACCESSWIRE / April 16, 2015 / NaturalNano, Inc. (PINKSHEETS:NNAN) (www.naturalnano.com) announced today a new breakthrough for Cancer targeting using our NaturalNano Halloysite modified with surfactants.

Dr. Michael King's laboratory at Cornell University in Ithaca NY is involved in cancer metastasis research. Recent work there utilized thin layers of naturally occurring Halloysite Nanotubes (HNT) as a nanostructured surface for the capture and manipulation of rare circulating tumor cells (CTCs) in patient blood. These CTCs are the cause of metastatic spread of cancer beyond the primary tumor being treated. Advances such as this hold promise for assisting clinicians to provide the most precise care possible to patients suffering from a broad range of cancer types. The abstract is available at www.naturalnano.com.

Dr. King states, "We were excited to find that we could tune the chemical properties of the halloysite to prefer cancer cells over white blood cells (or vice versa), even without resorting to the use of antibodies. We are learning more about the surface of cancer cells every day with this research."

James Wemett, NaturalNano CEO, said "We are pleased that Dr. King's lab continues to experience success with NNAN's HNT. Dr. King's work continues to expand our understanding of the potential role that HNT may play in life science applications."

NaturalNano, Inc. located in Rochester, New York, is engaged in the development and commercialization of material additives based on proprietary nanomaterial technology utilizing Halloysite Nanotubes (HNTs). The company provides industry with additives designed to improve the processing characteristics and mechanical properties of engineering thermoplastics, and additives designed to optimize the release of active agents such as vitamins and fragrance in cosmetic products. NaturalNano holds patents relating to the commercial use of HNTs in composite materials as well as specialized techniques used in the refinement and processing of HNTs and intermediaries that it ships to customers worldwide. HNT materials used as a surface treatment have also shown promise in medical research devoted to stem cell collection and in trapping circulating cancer cells. The company is also exploring surface treatments relating to improved adhesion of protective coatings for polymer components used in numerous commercial applications. Purchase samples on our web.

ViralProtec, www.viralprotec.com a wholly owned subsidiary of NaturalNano, is a reseller for best practices Ebola personal protective equipment (PPE) and ancillary supplies. Our mission is to provide personal protective equipment for all ones infectious patient care needs that meet or exceed CDC and WHO guidelines.

Cautionary Statement Regarding Forward-Looking Statements: Contains forward-looking statements regarding future events and future performance that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano's filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-K and quarterly reports on Form 10-Q filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports filed with the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.

Contact:

Jim Wemett
NaturalNano, Inc.
585-267-4848
info@naturalnano.com

SOURCE: NaturalNano, Inc.